Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Fuji
Dow
Teva
Covington
Express Scripts
Fish and Richardson
AstraZeneca
Merck
Harvard Business School

Generated: October 21, 2017

DrugPatentWatch Database Preview

Sankyo Company Profile

« Back to Dashboard

What is the competitive landscape for SANKYO, and what generic alternatives to SANKYO drugs are available?

SANKYO has three approved drugs.

There are two US patents protecting SANKYO drugs.

There are forty-five patent family members on SANKYO drugs in thirty-six countries and one supplementary protection certificate in one country.

Summary for Applicant: Sankyo

International Patents:45
US Patents:2
Tradenames:2
Ingredients:2
NDAs:3
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-003Aug 4, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-001Jan 29, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-002Jan 29, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
Sankyo
BANAN
cefpodoxime proxetil
TABLET;ORAL050687-001Aug 7, 1992DISCNNoNo► Subscribe► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-001Jan 29, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
Sankyo
BANAN
cefpodoxime proxetil
FOR SUSPENSION;ORAL050688-002Aug 7, 1992DISCNNoNo► Subscribe► Subscribe► Subscribe
Sankyo
BANAN
cefpodoxime proxetil
TABLET;ORAL050687-002Aug 7, 1992DISCNNoNo► Subscribe► Subscribe► Subscribe
Sankyo
BANAN
cefpodoxime proxetil
FOR SUSPENSION;ORAL050688-001Aug 7, 1992DISCNNoNo► Subscribe► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-002Jan 29, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-003Aug 4, 1997DISCNNoNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Sankyo

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-002Jan 29, 1997► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-001Jan 29, 1997► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-003Aug 4, 1997► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-003Aug 4, 1997► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-003Aug 4, 1997► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-001Jan 29, 1997► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-002Jan 29, 1997► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-003Aug 4, 1997► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-002Jan 29, 1997► Subscribe► Subscribe
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-003Aug 4, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expirations for SANKYO

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe
► Subscribe ► Subscribe

Non-Orange Book Patents for Sankyo

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,972,973 Sulfonylurea-glitazone combinations for diabetes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sankyo Drugs

Country Document Number Estimated Expiration
Austria293980► Subscribe
Peru74399► Subscribe
Argentina020973► Subscribe
Norway993982► Subscribe
Japan2002529417► Subscribe
Honduras1997000167► Subscribe
Australia741215► Subscribe
Eurasian Patent Organization199900725► Subscribe
Guatemala199800037► Subscribe
Honduras1999000184► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sankyo Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB97/084United Kingdom► SubscribePRODUCT NAME: TROGLITAZONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 10949/0277 19970729; UK 10949/0278 19970729; UK 10949/0279 19970729; UK 06384/0005 19970729; UK 06384/0006 19970729; UK 06384/0007 19970729
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Argus Health
Citi
Daiichi Sankyo
Boehringer Ingelheim
Medtronic
Express Scripts
Teva
Harvard Business School
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot